A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT06768489
Trial Phases:	Phase I	Protocol IDs:	79635322MMY1002 (primary) NCI-2026-05555 2024-515316-44-00 79635322MMY1002
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06768489

Summary

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe
effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322
treatment regimen in combination with daratumumab with or without lenalidomide or with
pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and
tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.